Search research articles
Contact Us
Filters
Showing results (51-60 of 72) with videos related to
Page
of 8
Sort By:
Cancer Research
|
August 27, 1999
The protein kinase C inhibitor CGP41251 suppresses cytokine release and extracellular signal-regulated kinase 2 expression in cancer patients
P Thavasu, D Propper, A McDonald, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 13, 2006
Detailed analysis of a randomized phase III trial: can the tolerability of capecitabine plus docetaxel be improved without compromising its survival advantage?
R Leonard, J O'Shaughnessy, S Vukelja, et al.
British Journal of Cancer
|
June 10, 2004
Phase I and pharmacokinetic (PK) study of MAG-CPT (PNU 166148): a polymeric derivative of camptothecin (CPT)
D Bissett, J Cassidy, J S de Bono, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 15, 2003
Use of positron emission tomography in pharmacokinetic studies to investigate therapeutic advantage in a phase I study of 120-hour intravenous infusion XR5000
D J Propper, J de Bono, A Saleem, et al.
British Journal of Cancer
|
December 21, 2006
A phase I trial of the selective oral cyclin-dependent kinase inhibitor seliciclib (CYC202; R-Roscovitine), administered twice daily for 7 days every 21 days
C Benson, J White, J De Bono, et al.
European Journal of Cancer (Oxford, England : 1990)
|
August 23, 2003
Phase I and pharmacokinetic study of Yondelis (Ecteinascidin-743; ET-743) administered as an infusion over 1 h or 3 h every 21 days in patients with solid tumours
C Twelves, K Hoekman, A Bowman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 15, 2000
Capecitabine, an oral fluoropyrimidine carbamate with substantial activity in advanced colorectal cancer: results of a randomized phase II study
E Van Cutsem, M Findlay, B Osterwalder, et al.
European Journal of Cancer (Oxford, England : 1990)
|
April 3, 2012
New prognostic factors and calculators for outcome prediction in patients with recurrent glioblastoma: a pooled analysis of EORTC Brain Tumour Group phase I and II clinical trials
Thierry Gorlia, Roger Stupp, Alba A Brandes, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 21, 2013
Randomised phase II study of axitinib or bevacizumab combined with paclitaxel/carboplatin as first-line therapy for patients with advanced non-small-cell lung cancer
C Twelves, E Chmielowska, L Havel, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 26, 1999
Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl)methacrylamide copolymer doxorubicin]: first member of a new class of chemotherapeutic agents-drug-polymer conjugates. Cancer Research Campaign Phase I/II Committee
P A Vasey, S B Kaye, R Morrison, et al.
Page
of 8
Search research articles
Search
Showing results (51-60 of 72) with videos related to
Sort By:
Page
of 8
Cancer Research
|
August 27, 1999
The protein kinase C inhibitor CGP41251 suppresses cytokine release and extracellular signal-regulated kinase 2 expression in cancer patients
P Thavasu, D Propper, A McDonald, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 13, 2006
Detailed analysis of a randomized phase III trial: can the tolerability of capecitabine plus docetaxel be improved without compromising its survival advantage?
R Leonard, J O'Shaughnessy, S Vukelja, et al.
British Journal of Cancer
|
June 10, 2004
Phase I and pharmacokinetic (PK) study of MAG-CPT (PNU 166148): a polymeric derivative of camptothecin (CPT)
D Bissett, J Cassidy, J S de Bono, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 15, 2003
Use of positron emission tomography in pharmacokinetic studies to investigate therapeutic advantage in a phase I study of 120-hour intravenous infusion XR5000
D J Propper, J de Bono, A Saleem, et al.
British Journal of Cancer
|
December 21, 2006
A phase I trial of the selective oral cyclin-dependent kinase inhibitor seliciclib (CYC202; R-Roscovitine), administered twice daily for 7 days every 21 days
C Benson, J White, J De Bono, et al.
European Journal of Cancer (Oxford, England : 1990)
|
August 23, 2003
Phase I and pharmacokinetic study of Yondelis (Ecteinascidin-743; ET-743) administered as an infusion over 1 h or 3 h every 21 days in patients with solid tumours
C Twelves, K Hoekman, A Bowman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 15, 2000
Capecitabine, an oral fluoropyrimidine carbamate with substantial activity in advanced colorectal cancer: results of a randomized phase II study
E Van Cutsem, M Findlay, B Osterwalder, et al.
European Journal of Cancer (Oxford, England : 1990)
|
April 3, 2012
New prognostic factors and calculators for outcome prediction in patients with recurrent glioblastoma: a pooled analysis of EORTC Brain Tumour Group phase I and II clinical trials
Thierry Gorlia, Roger Stupp, Alba A Brandes, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 21, 2013
Randomised phase II study of axitinib or bevacizumab combined with paclitaxel/carboplatin as first-line therapy for patients with advanced non-small-cell lung cancer
C Twelves, E Chmielowska, L Havel, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 26, 1999
Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl)methacrylamide copolymer doxorubicin]: first member of a new class of chemotherapeutic agents-drug-polymer conjugates. Cancer Research Campaign Phase I/II Committee
P A Vasey, S B Kaye, R Morrison, et al.
Page
of 8